Clinical and pharmacological comparison between aceclofenac and diclofenac: which nsaid is better?
Abstract
Aceclofenac and Diclofenac are both non-steroidal anti-inflammatory drugs (NSAIDs) commonly Used to treat pain and inflammation, especially in conditions like arthritis. Both drugs work by blocking the action of cyclooxygenase (COX) enzymes, which produce substances that cause pain and swelling in the body. However, Aceclofenac is a derivative of Diclofenac and shows some Differences in terms of clinical effectiveness and tolerability. Aceclofenac is often considered a better option for long-term treatment due to its better gastrointestinal safety profile. It causes fewer side effects like stomach pain, nausea, vomiting, and Ulcers when compared to Diclofenac. This makes Aceclofenac more suitable for patients who are at Risk of gastrointestinal issues. Additionally, studies suggest Aceclofenac provides similar or even Greater pain relief than Diclofenac, with fewer complications. In terms of pharmacokinetics; both drugs are effective but differ slightly in their half-life (T½), dose, Elimination rate, and bioavailability. Aceclofenac has a half-life of about 4 hours and is usually given in a dose of 100 mg twice daily. Diclofenac has a shorter half-life and may need more frequentDosing. In conclusion; both Aceclofenac and Diclofenac are effective NSAIDs. The choice between them Depends on the patient’s condition, medical history, and tolerance to side effects. Aceclofenac is generally preferred for its better efficacy and lower gastrointestinal side effects, especially in long term use.
Keywords:
Aceclofenac, Diclofenac, osteoarthritis, Safety, Meta analysisDOI
https://doi.org/10.70604/learnint.v2i3.103References
1. Goldstein JL, Correa P, Zhao WW, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitors, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001; 96: 1019-27.
2. Hawkey C, Laine L, Simon T, et al. Comparison of the effect of rofecoxib (a cyclooxygenase-2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum 2000; 43: 370-7.
3. Juni P, Nartey L, Reichenbach S, et al. Rosk of cardiovascular events and refecoxib: cumulative meta-analysis. Lancet 2004; 364: 2021-9.
4. E. C Huskisson, M Irani, F Murray. A large prospective open-label, multicentre SAMM study comparing the safety of aceclofenac with diclofenac in patients with rheumatic disease. European Journal of Rheumatology and Inflammation 2000; 17-1.
5. Ernst-Martin Lemmel, Burkhard Leeb, Johan De Bast et. Al. Patient and Physician Satisfaction with Aceclofenac: Results of the European Observational Cohort Study. Current Medical Reasearch and Opinion 2002; 18: 146 -153.
6. Niedziałek D, Tłustochowicz W. Leczenie bólu wchorobach reu- matycznych. Post Nauk Med 2012; 25: 109-114.
7. Pereira-Leite C, Nunes C, Reis S. Interaction of nonsteroidal anti-inflammatory drug with membranes: in vitro assessment and relevance for their biological actions. Prog Lipid Res 2013; 52: 571-584.
8. Międzyborski R. Kierunki poszukiwań izastosowanie nie- steroidowych leków przeciwzapalnych. Postepy Hig Med Dosw 2004; 58: 438-448.
9. Rupiński R. Diklofenak – sprawdzony lek wleczeniu bólu wchorobach reumatycznych. Czy powinniśmy się go obawiać? Świat Med Farm 2017; 4: 94-100.
10. Rajtar-Cynke G. Farmakologia. Czelej, Lublin 2015.
11. Costa BR, Reichenbach S, Keller N, et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: anetwork meta-analysis. Lancet 2017; 390: e21-e33.
12. Bjordal JM, Klovning A, Ljunggren AE, Slordal L. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta-analysis of randomised placebo-controlled trials. Eur J Pain. 2007;11(2):125–138.
13. Neame R, Zhang W, Doherty M. A historic issue of the Annals: three papers examine paracetamol in osteoarthritis. Ann Rheum Dis. 2004; 63(8):897–900.
14. Baraf HS, Gold MS, Clark MB, Altman RD. Safety and efficacy of topical diclofenac sodium 1% gel in knee osteoarthritis: a randomized controlled trial. Phys Sportsmed. 2010;38(2):19–28.
15. Patil PR, Jaida J, Palani A, Rao K, Anandam B. A comparative study of efficacy and safety of di-clofenac and aceclofenac in the treatment of osteoarthritis patients. Journal of Drug Delivery & Therapeutics 2012; 2: 139-43. [CrossRef]
16. Sehgal A, Sehgal VK, Singh R. Comparison of efficacy and tolerability of aceclofenac and di-clofenac in osteoarthritis of knee joint. Int J Med Dent Sci 2015; 4: 745-50. [CrossRef]
17. Perez Busquier M, Calero E, Rodriguez M, Cas-tellon Arce P, Bermudez A, Linares LF, et al. Comparison of aceclofenac with piroxicam in the treatment of osteoarthritis. Clin Rheumatol 1997; 16: 154-9. [CrossRef]
18. Torri G, Vignati C, Agrifoglio E, Benvenuti M, Ce-ciliani L, Raschella BF, et al. Aceclofenac versus piroxicam in the management of osteoarthritis of the knee: a double-blind controlled study. Thera-peutic research 1994; 55: 576-83. [CrossRef]
19. Batlle-Gualda E, Ivorra JR, Mola EM, Abello JC, Ferrando LFL, Molina JT, et al. Aceclofenac vs paracetamol in the management of symptom-atic osteoarthritis of the knee: a double blind 6 week randomized controlled trial. Osteoarthri-tis Cartilage 2007; 15: 900-8. [CrossRef]
20. Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE. Comparative effectiveness of phar-macologic interventions for k nee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med 2015; 162: 46–54. [CrossRef]
21. Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Tschannen B, Altman DG, et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemi-ological study. BMJ 2010; 341: c3515. [CrossRef]
22. Litwic A, Edwards MH, Dennison EM, Cooper C. Epidemiology anvd burden of osteoarthritis. Br Med Bull 2013; 105: 185-99. [CrossRef]
23. Brizuela NY, Montrull HL, Demurtas SL, Meirovich CI. Articular cartilage in osteoarthritic patients: effects of diclofenac, celecoxib and glucosamine sulfate on inflammatory markers. Rev Fac Cien Med Univ Nac Cordoba 2007; 64: 9-15.
24. Moote C. Efficacy of nosteroidal anti-inflammatory drugsin the management of postoperative pain. Drugs1992;44(Suppl.5):14-30.
25. Dooley M C, Spencer M. Aceclofenac : a reappraisal of itsuse in the management of pain and rheumatic disease. Drugs2001;61:1351-78.
26. McCormack K. The spinal actions of nonsteroidal anti-inflammatory drugs and the dissociation between the anti-inflammatory and analgesic effects. Drugs1994a;47(Suppl.5):28-45.
27. McCormack K. Nonsteroidal anti-inflammatory drugs andspinal nociceptive processing. Pain 1994b;59:9-43
28. Walker-Bone K, Javaid K, Arden N, et al. Regular review: medical management of osteoarthritis. BJM 2000; 321: 936-40.
29. Jämsen E, Jäntti P, Puolakka T, et al. Primary knee replacement for primary osteoarthritis in the aged: gender differences in epidemiology and preoperative clinical state.Aging Clin Exp Res. 2012 Dec;24(6):691-8.
30. Sarzi-Puttini P, Cimmino MA, Scarp R, et al. Osteoarthritis: an overview of the disease and its treatment strategies. Semin Arthritis Rheum 2005; 35: 1-10.
31. Kumar & Clerk. 5th Edition, M. Shipley, CM Black, J Compston & D O Gradiagh. Clinical Medicine. Page No. 533.
32. 32.Medicinenet.com/ Osteoarthritis/ article.html.2007. William C., Shiel J., MD.
33. Liu-Bryan R Synovium and the innate inflammatory network in osteoarthritis progression. Curr Rheumatol Rep. 2013 May;15(5):323. doi: 10.1007/s11926-013-0323-5.
Published
Abstract Display: 571 
PDF Downloads: 179 How to Cite
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Deprecated: json_decode(): Passing null to parameter #1 ($json) of type string is deprecated in /home/lapinjournals/domains/lapinjournals.com/public_html/plugins/generic/citations/CitationsPlugin.php on line 68
.